4-[3-[(1,1-二甲基乙基)氨基]2-羟基丙氧基]-1,3-二氢-2H-苯并咪唑-2-盐酸盐 | 64208-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 4-[3-[(1,1-二甲基乙基)氨基]2-羟基丙氧基]-1,3-二氢-2H-苯并咪唑-2-盐酸盐
• 英文名称: 4-(3-(tert-butylamino)-2-hydroxypropoxy)-1H-benzo[d]imidazol-2(3H)-one hydrochloride
• 英文别名: 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one;hydrochloride
• CAS: 64208-32-8
• 化学式: C14H22ClN3O3
• 分子量: 315.79
• InChiKey: YQVFCYCTITZLSX-UHFFFAOYSA-N

物化性质

• 溶解度：
  二甲基亚砜：>10mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1.41
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  82.6
• 氢给体数：
  5
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,3-epoxypropoxybenzimidazole-2-one 、 叔丁胺 生成 4-[3-[(1,1-二甲基乙基)氨基]2-羟基丙氧基]-1,3-二氢-2H-苯并咪唑-2-盐酸盐
  参考文献：
  名称：

  JAEGGI, K. A.;OSTERMAYER, F.;SCHROETER, H.

  摘要：

  DOI：

文献信息

• Dopamine analog amide
  申请人：——

  公开号：US20010056116A1

  公开（公告）日：2001-12-27

  The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

  该发明涉及使用脂肪酸载体和神经活性药物形成前药。该前药在胃和血液流动环境中稳定，并可通过口服递送。该前药容易穿过血脑屏障。一旦进入中枢神经系统，前药被水解成脂肪酸载体和药物以释放药物。在首选实施方式中，载体是4,7,10,13,16,19二十二碳六烯酸，药物是多巴胺。两者都是中枢神经系统的正常成分。药物和载体之间的共价键通常是酰胺键，这种键可以在胃的条件下存活。因此，前药可以被摄入，并且不会在胃中完全水解成载体分子和药物分子。
• PREVENTIVE/REMEDY FOR FREQUENT URINATION AND URINARY INCONTINENCE
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP0958835A1

  公开（公告）日：1999-11-24

  The present invention relates to a novel drug for the prevention or treatment of pollakiuria and urinary incontinence which comprises as an active ingredient a β3-adrenoceptor stimulating agent, which exerts potent relaxing effects on human bladder smooth muscle.

  本发明涉及一种用于预防或治疗花粉尿症和尿失禁的新型药物，其活性成分包括一种 β3-肾上腺素受体刺激剂，它能对人体膀胱平滑肌产生强效松弛作用。
• Reprogramming fibroblasts into cardiomyocytes
  申请人：The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone

  公开号：US10144915B2

  公开（公告）日：2018-12-04

  Compositions and methods are described herein for chemically inducing cells that express a single pluripotency transcription factor to change their differentiation state and become cardiac cells, cardiac progenitor cells, cardiomyocytes, or a combination thereof.

  本文描述了通过化学方法诱导表达单一多能性转录因子的细胞改变其分化状态，使其成为心脏细胞、心脏祖细胞、心肌细胞或其组合的组合物和方法。
• DRUG FOR RELIEVING PAIN AND PROMOTING THE REMOVAL OF CALCULI IN UROLITHIASIS
  申请人：KISSEI PHARMACEUTICAL CO., LTD.

  公开号：EP0872246B1

  公开（公告）日：2003-02-19
• A METHOD OF CHARACTERIZING FLUORESCENT MOLECULES OR OTHER PARTICLES USING GENERATING FUNCTIONS
  申请人：Evotec OAI AG

  公开号：EP1175602B1

  公开（公告）日：2003-03-19